



Announcement Summary

Entity name

AUSTRALIAN CLINICAL LABS LIMITED

Date of this announcement

Wednesday December 20, 2023

The +securities the subject of this notification are:

☒ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

| ASX +security code | Security description | Total number of +securities to be issued/transferred | Issue date |
|--------------------|----------------------|--|------------|
| ACLAL | PERFORMANCE RIGHTS | 680,644 | 19/12/2023 |

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

AUSTRALIAN CLINICAL LABS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

94645711128

1.3 ASX issuer code

ACL

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

20/12/2023



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

☒ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☒ has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

ACLAL : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

19/12/2023

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class☒ Yes**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**☒ Yes**Provide details of the KMP or +associates being issued +securities.**

| Name of KMP | Name of registered holder | Number of +securities |
|---|---------------------------|-----------------------|
| Melinda McGrath (Chief Executive Office and Executive Director) | Same | 395,490 |
| James Davison (Chief Financial Officer) | Same | 177,531 |

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

The full terms and conditions of the ACL Long Term Variable Remuneration Plan were released to the ASX Market Announcements Platform on 14 May 2021 (available at <https://announcements.asx.com.au/asxpdf/20210514/pdf/44wh9wybx5bksz.pdf>)

Any other information the entity wishes to provide about the +securities the subject of this notification



Issue details

Number of +securities

680,644

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

| ASX +security code and description | Total number of +securities on issue |
|------------------------------------|--------------------------------------|
| ACL : ORDINARY FULLY PAID | 201,834,015 |

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|------------------------------------|--------------------------------------|
| ACLAD : SERVICE RIGHTS | 1,058,527 |
| ACLAL : PERFORMANCE RIGHTS | 2,421,330 |



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

☒ Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13